We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A modified human ELISPOT assay to detect specific responses to primary tumor cell targets.
- Authors
Malyguine, Anatoli; Strobl, Susan L.; Shafer-Weaver, Kimberly A.; Ulderich, Tracy; Troke, Angela; Baseler, Michael; Kwak, Larry W.; Neelapu, Sattva S.
- Abstract
Background: The desired outcome of cancer vaccination is to induce a potent T cell response which can specifically recognize and eliminate autologous tumor cells in vivo. Accordingly, immunological assays that demonstrate recognition of native tumor cells (tumor-specific) may be more clinically relevant than assays that demonstrate recognition of tumor protein or peptide (antigen-specific). Methods: Towards this goal, we adapted the IFN-? ELISPOT assay to measure immune responses against autologous primary tumor cells in vaccinated cancer patients. As a model system to develop the assay, we utilized peripheral blood mononuclear cells (PBMC) directly isolated from follicular lymphoma patients vaccinated with tumor-derived idiotype protein. Results: After optimizing several variables, we demonstrated that the modified IFN-γ ELISPOT assay could be used to reliably and reproducibly determine the tumor-reactive T cell frequency in the PBMC of these patients. The precursor frequency of tumor-reactive T cells was significantly higher in the postvaccine PBMC, compared with prevaccine samples in all patients tested. Furthermore, the specificity of these T cells was established by the lack of reactivity against autologous normal B cells. Conclusions: These results demonstrate the feasibility of quantitating tumor-specific T cell responses when autologous, primary tumor cells are available as targets.
- Subjects
CANCER vaccines; T cells; B cells; PEPTIDES; IMMUNE response; CLINICAL trials
- Publication
Journal of Translational Medicine, 2004, Vol 2, p9
- ISSN
1479-5876
- Publication type
Article
- DOI
10.1186/1479-5876-2-9